Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)
Crossref DOI link: https://doi.org/10.1007/s13340-014-0182-y
Published Online: 2014-07-04
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kashiwagi, Atsunori
Shiga, Takanori
Akiyama, Noriko
Kazuta, Kenichi
Utsuno, Atsushi
Yoshida, Satoshi
Ueyama, Eiji
Text and Data Mining valid from 2014-07-04